Key result
New promising molecules for the treatment of chronic kidney disease may change the future management of high blood pressure in this population by targeting pathophysiological interactions.
Why the study?
Hypertension and CKD are closely interlinked pathophysiologic states where high BP drives disease progression and CVD risk, necessitating optimal BP management.
Optimal blood pressure management and emerging therapeutic molecules are crucial for breaking the pathophysiological cycle between hypertension, chronic kidney disease, and cardiovascular disease.
CV risk dominates mortality in hypertensive CKD; leaves open optimal BP targets across ages.
BACKGROUND: Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that high blood pressure (BP) is an independent risk factor for disease progression in both adult and pediatric patients with kidney disorders and progressive decline in kidney function can conversely lead to worsening BP control. SUMMARY: Hypertension in CKD is not only associated with GFR loss, but increases cardiovascular risk, which is the leading source of mortality and morbidity in this population. Given this complex relationship between hypertension, CKD, and CVD, an optimal management of BP in CKD is mandatory to break an established vicious pathophysiological cycle that leads to adverse outcomes. KEY MESSAGES: New promising molecules for the treatment of CKD, with interesting mechanisms, particularly regarding their pathophysiological interactions with arterial hypertension, are available or under development and in the very next future they may change the way we treat high BP in CKD patients.
No takes yet. Share an insight, caveat, or question.
Pascalis et al. (2024) conducted a review in Hypertension and chronic kidney disease (CKD). New promising molecules for the treatment of CKD was evaluated. New promising molecules for the treatment of chronic kidney disease may change the future management of high blood pressure in this population by targeting pathophysiological interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: